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Background: Warfarin is the most widely prescribed anticoagulant for the prevention and treatment of thromboembolic
events. Although highly effective, the use of warfarin is limited by a narrow therapeutic range combined with a more
than ten-fold difference in the dose required for adequate anticoagulation in adults. An optimal dose that leads to a
favourable balance between the wanted antithrombotic effect and the risk of bleeding as measured by the prothrombin
time International Normalised Ratio (INR) must be found for each patient. A model describing the time-course of the INR
response can be used to aid dose selection before starting therapy (a priori dose prediction) and after therapy has been
initiated (a posteriori dose revision).
Results: In this paper we describe a warfarin decision support tool. It was transferred from a population PKPD-model for
warfarin developed in NONMEM to a platform independent tool written in Java. The tool proved capable of solving a
system of differential equations that represent the pharmacokinetics and pharmacodynamics of warfarin with a
performance comparable to NONMEM. To estimate an a priori dose the user enters information on body weight, age,
baseline and target INR, and optionally CYP2C9 and VKORC1 genotype. By adding information about previous doses
and INR observations, the tool will suggest a new dose a posteriori through Bayesian forecasting. Results are displayed
as the predicted dose per day and per week, and graphically as the predicted INR curve. The tool can also be used to
predict INR following any given dose regimen, e.g. a fixed or an individualized loading-dose regimen.
Conclusions: We believe that this type of mechanism-based decision support tool could be useful for initiating and
maintaining warfarin therapy in the clinic. It will ensure more consistent dose adjustment practices between prescribers,
and provide efficient and truly individualized warfarin dosing in both children and adults.
Keywords: Anticoagulation, Bayesian forecasting, Dose individualization, Population PK/PD-models, WarfarinBackground
Warfarin is one of the most commonly prescribed anti-
coagulants in both adults and children [1], with over 33
million prescriptions in 2011 [2]. In spite of the recent
introduction of the new oral anticoagulants (NOACs),
i.e. dabigatran, rivaroxaban and apixaban, warfarin still
remains the most prescribed anticoagulant with 90% of
Swedish patients receiving warfarin and only 10% receiv-
ing a NOAC during 2013 [3]. Although it has been in
clinical use for over 50 years, warfarin therapy is still
challenging due to a narrow therapeutic range and* Correspondence: mia.wadelius@medsci.uu.se
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unless otherwise stated.considerable variability in response to a given dose.
Known contributing factors to the between- and within-
subject variability among adult patients include, age,
concurrent medications and/or health conditions, vita-
min K intake and genetic polymorphisms in two genes,
CYP2C9 and VKORC1 [4-6]. In a systematic review and
meta-analysis, patients with atrial fibrillation (AF) re-
ceiving warfarin spent 61% of the time within, 13%
above, and 26% below the target INR of 2-3 [7]. In a US
study that was published in 2011, the frequency of
warfarin-induced bleeding was reported to be 15% to
20% per year, with life-threatening or fatal bleeding rates
as high as 1% to 3% per year [8]. Annual total health
care costs were estimated to be 65% and 49% higher
for AF patients with a warfarin-induced intracranialral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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spectively, than the costs for patients with no bleeding
events [9].
Dose individualization to minimize the risk for over-
or under-dosing can be made i) before starting therapy
(a priori) and/or ii) after therapy has been initiated (a
posteriori) and may range in complexity from body size
based dosing to utilization of advanced mechanism
based mathematical and statistical models. There are
several published pharmacogenetic prediction models
for a priori dose individualization of warfarin for both
adults [4,5,10] and children [11-13]. These dosing algo-
rithms aim to predict the expected maintenance dose. A
more refined way to achieve individualized dosing is to
combine methods for a priori individualization with
methods for a posteriori dose revisions, using a Bayesian
approach [14,15]. The latter utilizes knowledge of the
population distribution of the model parameters for the
drug. The most likely parameters for an individual can
be obtained using measurements of drug concentrations
[16,17] or drug responses [18,19]. These parameters can
be used to calculate the dose that most probably results
in the target response in that particular individual. By
using a predictive model combined with Bayesian fore-
casting, warfarin dosing can be truly personalized, result-
ing in rapid achievement of therapeutic anticoagulation
without increasing the risk of over-anticoagulation.
In this paper we present a warfarin dose decision tool
(available as Additional file 1) developed from a pub-
lished population model for warfarin. The model is
founded on pharmacokinetic (PK) and pharmacody-
namic (PD) principles [20-22] and is schematically pre-
sented in Figure 1. The tool can be used a priori to
predict the most probable dose to reach a given targetFigure 1 Schematic picture of PKPD-based warfarin model. This is a sc
for warfarin. The predictors necessary for individual dose predictions (e.g. C
INR) are not included in the picture.INR, or to predict the most probable INR response to a
given dose. It can also be used a posteriori to guide dose
revisions using a Bayesian forecasting method. The
model was developed on longitudinal data from more
than 1,500 warfarin treated adults [20-21], and then
bridged theoretically to children 0.18 years old [22].
There is a time delay between warfarin dosing and INR
response, and this is captured in the model by inclusion
of a transduction model, consisting of two parallel com-
partment chains, where n is the number of compart-
ments in each chain and MTT is the mean transit time
through each chain. Two parallel chains were necessary
to describe the exposure–response relationship over
time, and is possibly a reflection of differences in half-
lives of the coagulation factors affected by warfarin and
that influences the INR response [20]. The general form
of the model is given by the following set of equations:
dA
dt
¼ −ke  A ð1Þ
DR ¼ ke  A ð2Þ
EFF ¼ EMAX
γ  DRγ
EDK 50γ þ DRγ ð3Þ
dC
dt






A represents the amount of drug in the body at any
time after one or more administrated doses. The first-
order elimination rate constant, ke (derived from the
ratio of the PK parameters clearance and volume of dis-
tribution, ke = CL/V), governs the level of drug amount
A at any given time and also the distribution of the drug
to the site of action (Equation 1). The dose rate DRhematic picture of the basic structure of the published PKPD-model
YP2C9 and VKORC1 genotype, age and bodyweight, baseline and target
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(Equation 3), defined by the parameters Emax (the max-
imum degree of inhibition which is set to 1) and EDK50
(the dose rate resulting in 50% of maximum inhibition),
determines the extent of inhibition of the vitamin K
cycle and the inhibition of coagulation factor activity.
dC/dt (Equation 4) describes the fraction of activated co-
agulation factors remaining at any given time. The initial
conditions of dA/dt and dC/dt are set to 0 and 1, re-
spectively, i.e. no drug in the body and 100% activity of
coagulation factors before start of therapy. The INR at
any given time is predicted by the following equation:
INRPRED ¼ INRBASE þ INRMAX
 1− C13 þ C23ð Þ=2ð Þ ð5Þ
INRBASE represents the INR at baseline (before war-
farin treatment), INRMAX is a theoretical maximal in-
crease from baseline INR (fixed to 20 as in [21]), and
C13 and C23 represents the coagulation factor activity in
the terminal compartment in each transit chain. Each
transit chain is defined by a set of differential equations
as exemplified below for the first chain C1:
dC11
dt
¼ 1−EFFð Þ  3
MTT 1
−C11  3MTT 1 ð6Þ
dC12
dt










A complete description of the underlying warfarin
model can be found in the papers describing the model
development in NONMEM [20-22]. NONMEM is the
most commonly used software for non-linear mixed ef-
fects modeling of PK and PD data [23].
Implementation
Tool development
One of the published warfarin models [22] was trans-
ferred from NONMEM to a new graphical user interface
built with Java Swing components using NetBeans [24].
NetBeans refers both to a platform framework for Java
applications, and to an open source integrated develop-
ment environment, supporting development of all types
of Java applications. The differential equations in the
Java application are solved using Heun’s method, a
second-order Runge-Kutta method, which is a numerical
procedure for solving ordinary differential equations that
is both fast and easy to implement using vectors. Heun’s
method is also stable for this type of differential equa-
tions and has a high numerical precision. The end result
is a Java application that, for a subject with a given set of
covariates, can estimate the maintenance dose for a pre-specified target INR or predict the INR response for a
pre-specified dose regimen. There are two main win-
dows in the application, one for a priori predictions and
one for a posteriori predictions. The rate constant ke is
referred to as k10 in the tool.A priori predictions
The tool needs input data regarding the patient in order
to operate. Data on age, weight, CYP2C9 and VKORC1
genotype, baseline INR and target INR range are re-
quired both for dose estimation and for INR prediction.
If genotype information is missing, the tool will use the
most common genotype combination, conditioned on
ethnicity [25,26]. This means that for CYP2C9 all sub-
jects with missing genotype information will be coded as
*1/*1 i.e. the genotype with the highest dose require-
ment. For VKORC1 the tool will use A/G for Caucasians
(intermediate dose requirement), A/A for Asians (low
dose requirement) and G/G for Africans (high dose re-
quirement). If baseline INR is missing the tool will use a
default value of 1. The dosing interval has a default value
of 24 hours, i.e. one dose per day, but this can be chan-
ged manually if another dosing interval is preferred.
Common to all a priori predictions is that the model will
use the typical (mean) parameter estimates conditioned
on the patient’s age, bodyweight and CYP2C9 and
VKORC1 genotype.Estimation of dose
To calculate the dose most likely to achieve the target
INR, the option “Estimate dose” is chosen; see example
in Figure 2. The tool uses the mean of the specified tar-
get INR interval as the target INR for which a dose
should be estimated. The tool starts with a daily dose of
10 mg and calculates the expected INR after 100 daily
administrations of the same dose, to ascertain that
steady state conditions are reached. Depending on if the
calculated INR is lower or higher than the target INR,
the dose will be adjusted automatically in an iterative
process until the calculated mean INR at steady state
equals the target INR (Target INR ± 1%). The criteria for
steady-state is met when the change in INR between two
doses does not exceed 1%. To illustrate the expected
time course to a therapeutic and stable INR, the output
is presented as a plot of the predicted typical INR curve
from the 1st dose until steady state is reached. In
addition, a text field shows the predicted maintenance
dose in mg/day, mg/week and the number of 2.5 mg tab-
lets per week that is closest to the estimated weekly
dose. The latter is an adaptation to Swedish conditions
where only a 2.5 mg tablet strength is marketed. The
target INR range is marked in the plot to support the in-
terpretation of the predicted INR curve.
Figure 2 Example of the a priori dose estimation function. This shows an example of an a priori dose estimation for a 5 year old child, with
bodyweight 20 kg, genotypes CYP2C9 *2/*2 and VKORC1 A/A, with a target INR of 2.0-3.0 and a baseline INR of 1.2. The estimated maintenance
dose is 0.7 mg/24h, or 4.9 mg/week. The graph indicate that with this dose regimen, time to reach a target INR is ~6 days, and time to steady
state is ~12 days.
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When the tool is used to predict an INR (See example in
Figure 3), the user has to specify the dose and the num-
ber of days this dose should be repeated. The output is
presented both as a plot of the predicted INR curve for
the number of days specified, and as a text field showing
the predicted INR at the end of this period. If steady
state conditions have been reached the tool will display
the mean INR over a dosing interval. If steady state con-
ditions are not yet reached, the presented value is theFigure 3 Example of the a priori INR prediction function. This shows an e
75 kg, genotypes CYP2C9 *3/*3 and VKORC1 A/G, with a target INR of 2.0-3.0 a
including a 3-day loading dose regimen of 7.5 mg, 5 mg and 5 mg (not seen
of 1.5 mg, is an INR of 2.57. The graph indicate that a target INR is reached aftpredicted INR at 16 hours after last dose. The time point
was chosen to reflect the clinical situation in Sweden,
where INR is commonly monitored in the morning ap-
proximately 16 hours after last dose. There is also an op-
tion to predict INR after administration of a loading
dose regimen. To do this “Starting doses” must be
ticked, and the “Set doses” window opened. The user
can specify a number of individual doses by entering the
dose per day. If individual doses are chosen for the first
three doses (e.g. Dose 1: 7.5 mg, Dose 2: 5 mg, Dose 3:xample of an a priori INR prediction for a 20 year old, with bodyweight
nd a baseline INR of 1. The predicted INR after a total of 15 doses,
here but defined in the Set doses option) and followed by daily doses
er ~3 days with this dose regimen.
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tion is set to 15, the tool will automatically use the dose
specified in the main window for the remaining 12
doses. Figure 3 shows the output from the example
above with a 3-day loading dose regimen followed by
1.5 mg per day on Day 4-15.
A posteriori predictions
Once treatment has been initiated and one or more INR
observations are available, the tool can be used to sug-
gest a tailored maintenance dose based on individualized
parameter estimates. This is done in several steps using
a Bayesian approach. The first step is to estimate indi-
vidual model parameters, and this is done using Powell’s
method. The tool then uses the individual model param-
eters in the next step, which can be either dose estima-
tion or INR prediction. As more observations become
available, the individual model parameters become more
refined and specific to the individual patient. This is ex-
pected to increase the accuracy and precision of the dose
and INR predictions.
Estimation of individual model parameters
For estimation of individual model parameters the tool
requires patient specific information on demographics,
initial warfarin doses and INR observations, including
time of dosing and blood sampling for INR. The infor-
mation can be entered either manually, or be imported
from an Excel-file (see Additional files 2 and 3 for details
on naming of files and required data format). When the
data have been entered, click on “Estimate” to get the in-
dividual model parameter values for k10 and EC50. The
output is presented in a new screen (see Figure 4) as a
text field showing the typical (mean) parameterFigure 4 Example of the estimation of individual parameters. This pro
model parameters, showing both typical and individual parameter estimate
(red) INR curves for a given dose history. The individually predicted INR is pestimates for k10 and EC50 and the individual parameter
estimates, and as a plot of the population predicted INR
curve (in black) and the individually predicted INR curve
(in red). The patient’s INR observations are also shown
in the plot, which gives the user a chance to evaluate the
individual fit. Optionally the individually predicted INR
curve can be presented with a 90% confidence interval,
to include uncertainty in the individual parameter esti-
mates and the residual variability due to e.g. random er-
rors in delivered dose, blood sampling time and/or INR
measurements. When the individual model parameters
have been estimated, select “Estimate Dose/INR” to get a
new screen with the options “Estimate dose” and “Pre-
dict INR”.
Estimation of dose
Figure 5 shows a screen shot of the dose estimation op-
tion. The tool now uses the individual model parameters
to suggest a tailored maintenance dose. The output is
presented as a plot, with the individually predicted INR
curve after administration of the tailored maintenance
dose, starting from its current position (Day 0 in the
plot). It is also presented as a text field showing the pre-
dicted dose in mg/day, mg/week and the corresponding
number of 2.5 mg tablets per week. The target INR
range will be displayed in the plot together with the indi-
vidually predicted INR curve.
Prediction of INR
When predicting INRs, the user has to specify a dose
and the number of days this dose should be repeated.
The output is a plot of the predicted INR curve for the
number of days specified, and a text field showing the
predicted INR at the end of the treatment period. Ifvides an example of the output from the estimation of individual
s, and the population predicted (black) and the individually predicted
resented with an optional 90% confidence interval.
Figure 5 Example of the a posteriori dose estimation function. This shows an example of an a posteriori dose estimation for a 1.53 year old
child, with bodyweight 20 kg, genotypes CYP2C9 *1/*1 and VKORC1 A/A, and target INR 2.0-3.0 and a baseline INR of 1 using the individual
model parameters estimated in Figure 4. The estimated a posteriori dose is 1.08 mg/24 h, or 7.56 mg/week. The graph shows the predicted INR
curve after administration of the estimated daily dose (1.08 mg).
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display the mean INR over the dosing interval. If steady
state conditions are not yet reached, the predicted INR
at 16 hours after last dose is presented. This function
may be useful e.g. in situations where it is not feasible to
administer the same dose every day with available for-
mulations. Thus, when different daily doses are required,
the tool can visualize the variability in INR response that
this regimen is expected to introduce. The tool can also
be used to predict when warfarin should be discontinued
to reach below a certain INR value at a given point in
time, which can be of use e.g. before a planned surgical
procedure.
Results and discussion
The computational performance of the Java-based tool
was evaluated by comparing the output with the POST-
HOC function in NONMEM version 7 as the reference.
This was done using treatment data (one to three INR
observations) from a total of 49 children [22]. A priori
predicted maintenance doses and empirical Bayes esti-
mates of individual parameters and a posteriori predic-
tions of maintenance doses from the tool and from
NONMEM were compared. Results from a priori com-
parisons are presented in Figure 6, and from a posteriori
comparisons in Figure 7. There were no differences in a
priori maintenance dose predictions with the Java based
tool compared to NONMEM, but a mean difference in a
posteriori maintenance dose predictions of 5.0% (SD
6.7%). There was a systematic difference in a posteriori
maintenance dose predictions, with a bias (mean predic-
tion error, MPE) of -0.104 mg and an imprecision(relative mean prediction error, RMPE) of 0.192 mg. Per-
formance was benchmarked on a MacBook Pro with a
3.06 GHz Intel Core 2 Duo processor. Run times for a
typical a priori prediction was a few seconds. For a pos-
teriori predictions, run times were correlated with the
length of the treatment history used for computation of
empirical Bayes estimates. However, total run times,
including estimation of a tailored maintenance dose, sel-
dom exceeded 1 minute. A typical run time for a poster-
iori prediction of dose from 7 days of treatment history,
including 3 INR observations, was less than 10 seconds.
The dose prediction tool is based on a published
population warfarin model for adults [21] that has been
theoretically bridged to children through the use of
physiological principles [22]. The model incorporates
age, bodyweight, baseline and target INR, and CYP2C9
and VKORC1 genotype (defined or assumed) for a priori
dose predictions, and uses doses and INRs from ongoing
treatment for a posteriori dose revisions. The warfarin
model was developed in NONMEM [23], which is the
most commonly used software for non-linear mixed ef-
fects modeling of clinical PK and PD data. Dose
optimization could in theory be performed using this
software, but there are several reasons for moving to an-
other environment. NONMEM, like other specialized
software for non-linear mixed effects modeling, has i) a
high knowledge threshold for use, ii) specific demands
for data input, and iii) requires licensing of a program.
All these aspects would impede the use of the model as
a dose decision tool. An advantage of the tool compared
with other warfarin dose algorithms, is that it can be
used to adjust warfarin dosing a posteriori due to other
Figure 6 Comparison of a priori dose predictions. This figure provides results from a comparison of a priori dose predictions from NONMEM
and the Java-based tool. The validation was performed using treatment data from 49 external children, and the results indicated no differences in
computational performance between the two methods.
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cluded in the prediction model. When the a posteriori
function is used, the tool will start by estimating individ-
ual model parameters based on the patient’s input data.
The individual model parameters can be seen as the pa-
tient’s warfarin phenotype, and determines how the pa-
tient most likely will respond to therapy. When theFigure 7 Comparison of individual parameter estimates and a posteri
of individual parameter estimates (K10 and EC50) and a posteriori dose pred
performed using treatment data from 49 external children, and the results
the two methods.individual model parameters are estimated all factors
that affect the PK or PD of warfarin, e.g. regular exercise,
vitamin K intake, interacting drugs or other medical
conditions, will be taken into account and influence dose
predictions. Another advantage of the tool is its ability
to handle INR observations under non-steady-state con-
ditions. INR observations that are measured duringori dose predictions. This figure provides results from comparisons
ictions from NONMEM and the Java-based tool. The validation was
indicated minor differences in computational performance between
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valuable information about an individual patient’s re-
sponse to warfarin, both concerning rate and extent.
The tool can use INR values from start of therapy and
provide estimates of the expected INR at steady state. In
theory, this means that patients can reach a stable main-
tenance dose in less time and with fewer dose adjust-
ments and INR measurements than an empirical dosing
regimen.
When comparing maintenance dose predictions from
NONMEM and the Java based tool, there was a system-
atic difference with a bias (MPE) of -0.104 mg and an
imprecision (RMPE) of 0.192 mg for the tool. These dif-
ferences are relatively small and are not expected to in-
fluence dose recommendations when considering the
limitations in available tablet strengths. That there is a
difference between the tool and NONMEM may be ex-
plained by differences in i) the optimization algorithm
used when estimating individual doses, and ii) the defin-
ition of target INR at steady state. The Java based tool
defines the target INR as the mean INR during a dosing
interval whereas NONMEM defines the target INR as
the INR at 16 hours post dose.
Conclusions
The predictive performance of the underlying published
warfarin model has been extensively evaluated and
shown to perform well in predicting the anticoagulant
response in both children and adults [19,21,22,27]. The
dosing tool needs to be evaluated prospectively before it
can be recommended for use routinely in a clinical set-
ting. However, even before a formal validation, it is pos-
sible to build confidence in the tool by using it for
prediction of INR. Irrespective of whether the dose ad-
ministered to a patient is derived from the tool or if it is
an empirical dose, its accuracy can be evaluated by com-
paring predicted and observed INR values. A major limi-
tation with the tool from a clinical perspective is that it
has no save or printing function. However, there is at
least one commercial dose-individualization software
tool that have our warfarin models implemented, which
has both a save and a printing function (www.doseme.
com.au). It is important to emphasize that this type of
decision support tool is not intended to substitute for
the care by a licensed health care professional, such as a
clinician, pharmacist or specialized nurse. It should ra-
ther be seen as a tool to help ensure efficient and con-
sistent dose adjustment practices between prescribers
and between different health care providers, irrespective
of target INR or target population.
Availability and requirements
Project name: Warfarin Dose Calculator 1.0.1
Project home page: www.warfarindoserevision.comOperating system(s): Platform independent
Programming language: Java
Other requirements: Java Runtime Environment (JRE)
1.7.0 or newer
License: Apache Open source
Any restrictions to use by non-academics: No
Additional files
Additional file 1: Warfarin Dose Calculator 1.0.1. Provides important
information on how to name data files for importation of treatment data
into the Warfarin Dose Calculator.
Additional file 2: Naming of data files. Provides a template for the
data required for importing a patient’s treatment history into the Warfarin
Dose Calculator.
Additional file 3: Format of treatment history. Provides the
Java-based decision support tool described in this paper.
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degree of inhibition; EDK50: dose rate resulting in 50% of maximum
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